NCT06948994: A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma
- State
- Not started
- Phase
- Phase 1 and Phase 2
- People
- 15 planned
- Started
- 1 May 2025
- Primary completion
- 30 Apr 2027
- Arms
- intervention arm
- Results
- None posted
- 29 Apr 2025: Trial registered